Skip to NavigationSkip to content

Top Ten most popular articles on Pharmafile.com this week

Published on 12/05/17 at 11:05am

It's been a bad week for several large pharmaceutical companies this week, with some major failures in clinical trials that saw one company resigned to the failure of a drug that was once touted as a future blockbuster. Beyond this, the new FDA head has been confirmed and there's been positive news for those living with HIV.

Check out the week's ten most popular articles on Pharmafile.com now!

10. Sanofi joins growing list of companies making pricing commitments

Sanofi joined an ever-growing list of pharmaceutical companies that have pledged to limit the levels of their price increases or to provide more transparency on pricing, by stating it will keep pricing in line with healthcare inflation.

9. Scott Gottlieb appointed to the FDA's top role

After months of scrutiny, Scott Gottlieb was finally confirmed as the new Commissioner of the FDA, following his nomination by President Trump back in March.

8. AZ asthma drug falls short in Phase 3 study

AstraZeneca and its global biologics research and development arm MedImmune has announced that asthma treatment tralokinumab has failed to achieve its primary endpoint in its first Phase 3 trial.

7. Teva and Active Biotech hit by Phase 3 drug failure

Teva and Active Biotech have been collaborating on the drug laquinimod since 2004 but it now looks like the work put in may not reap any reward after the companies were forced to admit failure in its most recent Phase 3 trial. A major blow to Teva who had once predicted the drug could support similar sales to Copaxone.

6. Study reveals EpiPens stay effective years after expiration date

Researchers took a selection of EpinPens and EpiPen Juniors to determine how rapidly the medical devices lost efficacy, finding that the EpiPens retained enough active ingredient to be medically effective four years after their expiry date.

5. European Commission warns UK over drug authorisation validity due to Brexit

The European Commission issued a warning to pharmaceutical firms in the UK over the validity of current and future drug authorisations in the wake of Brexit.

4. HIV life expectancy boosted 10 years by new drugs

The latest research has revealed that those living with HIV can expect to live to an average age close to 70 years old, a 10-year improvement over those beginning treatment in 1996.

3. Weight loss pill treatment rejected by NICE

NICE announced, in an Appraisal Consultation Document, that it is not able to recommend Orexigen’s Mysimba as a weight loss treatment.

2. Roche blockbuster immunotherapy Tecentriq outclassed by chemo in latest trial

It was revealed this week that Roche’s immuno-oncology drug Tecentriq (atezolizumab) failed to hit its primary endpoint in a follow-up trial investigating its efficacy in treating advanced bladder cancer.

1. Patient reported outcomes: Putting the patient first

Our most popular story of the week was our recent feature on patient reported outcomes. With clinical practice marching towards a more precision-oriented methodology, assessment of treatment efficacy is undergoing a transformation and we covered the area in detail.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings